Mriglobal
Mriglobal, doing business as Midwest Research Institute, is a 501(c)(3) not-for-profit research organization that provides scientific research, testing, training, and product development services to federal and commercial clients. The company specializes in areas such as medical countermeasure development, biosafety testing, threat detection technologies, and specialized training programs. Mriglobal conducts over $110 million in annual research for federal agencies including the Department of Health and Human Services, Department of Defense, and Department of Homeland Security. Through federal contract and grant awards, Mriglobal delivers a wide range of capabilities including analytical testing, biorepository management, pharmaceutical manufacturing, and infectious disease research.
Mriglobal has received numerous prime federal contract awards for diverse projects across multiple agencies. For the Department of Health and Human Services, Mriglobal has provided services such as drug toxicity testing, stability studies of investigational drugs, and maintenance of chemopreventive agent repositories for the National Institutes of Health. The company has also supported the Centers for Disease Control and Prevention with bacterial panel production and laboratory response network services. For the Department of Defense, Mriglobal has conducted research on nerve agent detection in military working dogs and provided biocontainment systems. The company has also supported the Department of Homeland Security with test and evaluation services for chemical countermeasures. Many of Mriglobal's contract awards involve specialized scientific equipment, biocontainment units, and laboratory services. The company frequently serves as both a prime contractor and subcontractor, partnering with universities, other research institutes, and small businesses to deliver comprehensive research and development services.
In terms of federal grant awards, Mriglobal has received funding to enhance its biorepository and life sciences capabilities. A $5 million grant from the Department of Health and Human Services is supporting the expansion of Mriglobal's biorepository facility in North Kansas City, Missouri, to advance the management of biologics and biological samples for clinical studies. Another grant is funding the expansion of life sciences capabilities at Mriglobal's headquarters to support research for multiple NIH organizations. As a subrecipient, Mriglobal has contributed to university-led research projects on topics such as dexamethasone therapy for ocular injuries from vesicating agents, development of antidotes for toxic gases, and sequencing of tick-borne viral disease agents. These grant-funded projects leverage Mriglobal's expertise in areas like analytical testing, animal studies, and specialized laboratory services.
Mriglobal holds several significant federal contract IDVs that enable agencies to rapidly procure its services. A $146.3 million IDV from the National Institute of Allergy and Infectious Diseases supports pre-clinical evaluation of infectious disease countermeasures. Another $49.7 million IDV from the National Center for Advancing Translational Sciences covers chemistry, manufacturing, and controls services for drug substance development. Mriglobal also holds a $100 million IDV from the Office of the Assistant Secretary for Preparedness and Response for biological animal model and medical countermeasure development. The company's IDVs span a range of capabilities including safety evaluation studies, diagnostic pre-clinical services, and rapid response research support. These vehicles allow agencies like NIH, CDC, and BARDA to issue task orders for Mriglobal's specialized scientific and technical services on an as-needed basis to support critical public health and national security programs.
HKQHNFKNKL15 541715
Not listed 425 Dr Martin Luther King Jr Blvd, Kansas City, MO 64110, USA
7/24/01 1/3/26 Sri International
Sri International is a non-profit research and development institute that provides a wide range of scientific, engineering, and technical services to the U.S. federal government through contracts and grants. Established in 1946 as Stanford Research Institute and later becoming independent, Sri International has expertise across disciplines including biomedical sciences, computing, defense technologies, education, and energy/environmental studies. The organization conducts research and development for government agencies like the Department of Defense, NASA, Department of Health and Human Services, and Department of Education, as well as commercial clients. Through federal contracts and grants, Sri International delivers specialized research, engineering, and technical services across numerous domains to advance innovation and address critical national needs.
Through federal contracts, Sri International supports projects advancing defense technologies, national security capabilities, and interdisciplinary research. For the Department of Defense, work includes developing sensors, communication systems, and data analytics tools for agencies like DARPA and the Air Force. Sri also performs substantial biomedical research for HHS, including preclinical studies, drug discovery, and public health initiatives for the NIH and its institutes. For NASA, Sri provides aerospace R&D services like advanced materials research. The company frequently partners as both a prime and subcontractor with major defense firms and research universities on contracts. Examples of specific contract work include animal model development for infectious diseases, chemical screening for contraceptive development, toxicology studies, and engineering support for defense systems. Most contract awards do not have small business set-asides, given Sri's large size and non-profit status.
Sri International's federal grant portfolio spans a variety of research areas aligned with its multidisciplinary expertise. For the National Science Foundation, Sri conducts computer science research on topics like artificial intelligence, cybersecurity, and data science. NIH grants fund biomedical studies in areas such as neuroscience, sleep disorders, and drug development. Department of Education grants support research on educational technologies, early childhood education, and STEM learning. NASA funds Sri's space science research through grant programs. As a large organization, Sri often serves as the prime recipient on grants, collaborating with university partners as subrecipients. The grants enable Sri to pursue early-stage research that can later transition into more applied contract work. Examples include studies on autism spectrum disorders, communication disorders in children, and ionospheric physics.
Sri International holds several indefinite delivery vehicles (IDVs) that allow federal agencies to efficiently procure its services. For the Department of Defense, Sri has IDVs with DARPA to provide R&D in emerging technologies like advanced materials, quantum computing, and biotechnology. NASA awarded Sri an IDV for aerospace research services at Ames Research Center. The NIH has multiple IDVs with Sri for biomedical research support, including drug development services for the National Cancer Institute and toxicology studies for the National Institute on Drug Abuse. The Department of Labor utilizes an IDV with Sri for policy research and program evaluation services. These vehicles streamline the process for agencies to access Sri's diverse technical capabilities through task order awards across a wide range of scientific and engineering domains.
SRG2J1WS9X63 541715
Not listed SRI International, 333 Ravenswood Ave, Menlo Park, CA 94025, USA
5/21/01 2/19/25 Technical Resources International, Inc.
Technical Resources International, Inc., doing business as Technical Resources Intl (TRI), is a minority-owned, woman-owned, Hispanic American-owned small business that specializes in providing comprehensive clinical research support services to federal health agencies. The company offers a wide range of services, including clinical trials execution, regulatory support, research operations, and specialized scientific services critical to advancing medical research and product development. TRI has extensive experience supporting biomedical research initiatives for various agencies, including the National Institutes of Health (NIH), Food and Drug Administration (FDA), Office of the Assistant Secretary for Preparedness and Response (ASPR), and National Library of Medicine (NLM).
Over the past decade, TRI has been awarded over $1.1 billion in federal contracts as a prime contractor, demonstrating its significant role in supporting government health research initiatives. Notable awards include a $333.7 million contract from the National Institute of Allergy and Infectious Diseases (NIAID) for Clinical Research Operations and Management Support, a $317.1 million contract from ASPR for clinical trial planning and execution services, and a $171.4 million contract from the National Cancer Institute (NCI) for clinical trials sponsor and regulatory management support. TRI has also received multiple awards from other NIH institutes for services such as pharmacokinetic analysis, data coordination for clinical studies, and regulatory affairs support. These contracts typically involve complex clinical research services, often focusing on infectious diseases, cancer, and other critical health areas. While most awards are not set aside, TRI has received some contracts designated for small businesses. The company's work spans a wide range of activities, including clinical trial management, regulatory submissions, safety monitoring, data analysis, and scientific support for various research programs.
TRI holds several significant Indefinite Delivery Vehicles (IDVs) that enable rapid procurement of its services across federal health agencies. These include a $548 million multiple-award IDV with NCI for the Cancer Trials Support Unit, a $545.4 million single-award IDV with NIAID for comprehensive and rapid response to research programs, a $400 million single-award IDV with ASPR for clinical trials planning and execution, and a $364.5 million multiple-award IDV with NIAID for preclinical and translational vaccine development services. These IDVs cover a wide range of services, from clinical trial support and regulatory affairs to vaccine development and data management. Task orders issued under these vehicles have supported critical research initiatives in areas such as HIV, cancer, and emerging infectious diseases. For example, under the ASPR IDV, TRI has received task orders for clinical research support services, including project management, site selection and monitoring, specimen and product management, and regulatory affairs. The NIAID IDVs have facilitated rapid response to research needs, including support for clinical trials, manufacturing and controls, nonclinical animal studies, analytics, bioinformatics, and regulatory services.
FAA2LVENETH4 541715
Not listed 6500 Rock Spring Dr #650, Bethesda, MD 20817, USA
9/27/01 7/24/25 Advanced Bioscience Laboratories, Inc.
Advanced Bioscience Laboratories, Inc. (ABL), doing business as Advanced Bioscience Laboratories Inc., is a leading contract research and manufacturing organization specializing in the development of gene therapies, vaccines, oncolytics, and immunotherapies. As a foreign-owned, for-profit manufacturer of goods, ABL provides a wide range of preclinical and clinical development services to support infectious disease research and product development initiatives for government agencies, academic institutions, and industry clients. The company's expertise spans biologics manufacturing, testing, storage, shipping, and quality assurance services. ABL has been awarded numerous federal contracts and grants, particularly from the National Institutes of Health (NIH) and Department of Health and Human Services (HHS), to advance the development of medical countermeasures for various infectious diseases and other health conditions.
Through its federal contract awards, ABL has provided a diverse array of goods and services to support preclinical and clinical development programs. These include cGMP manufacturing of vaccines and biologics, process development, analytical testing, stability studies, and project management for infectious disease countermeasures such as HIV, influenza, and other vaccines and therapeutics. ABL has performed work for multiple NIH institutes, including the National Institute of Allergy and Infectious Diseases (NIAID), National Cancer Institute (NCI), and National Institute of Neurological Disorders and Stroke (NINDS). The company has contributed to various programs, including HIV microbicides and biomedical prevention, pediatric drug formulation development, and cancer prevention initiatives. Notable projects include the manufacture of glycopeptide immunogen nanoparticle vaccines, development of bitter taste receptor blockers for pediatric medicines, and production of vaccines targeting frame-shift mutations in tumors. ABL's contracts typically do not have set-aside designations, reflecting its status as a large business in the federal contracting landscape.
ABL's involvement in federal grant programs has primarily been as a subcontractor to academic institutions. The company has supported grants focused on vaccine development and immunology studies. For instance, ABL has worked on a project to develop MecVax, a cross-protective subunit vaccine for enterotoxigenic E. coli (ETEC), in collaboration with the University of Illinois. Another significant grant-funded project involved toxicology studies and assay verification for a gonococcal peptide vaccine (TMCP2) in partnership with the University of Massachusetts Medical School. In these projects, ABL's role typically includes conducting toxicology studies, verifying immunological assays such as ELISAs and bactericidal assays, and providing technical expertise in vaccine development and testing.
ABL holds several Indefinite Delivery Vehicles (IDVs) with federal agencies, demonstrating its broad capabilities in biopharmaceutical research and development. A notable IDV is with NIAID for the Diagnostics Pre-Clinical Services Program, valued at $24 million, which supports in vitro diagnostic development. Another significant IDV is with NINDS for Manufacturing and Nonclinical Studies Support for the Development of Therapeutic Biotechnology Products for Neurological-related Disorders, with a ceiling of $149.2 million. ABL also holds an IDV with NIAID for Resources to Advance Pediatrics and HIV Prevention Science, valued at $98.9 million, covering a range of preclinical development support services. Additionally, the company has an IDV with NCI for the PREVENT Cancer Preclinical Drug Development Program, focused on cGMP production of vaccines and biologicals for cancer prevention. These IDVs collectively demonstrate ABL's comprehensive capabilities in supporting the development of vaccines, therapeutics, and diagnostics across multiple disease areas and federal health agencies.
MK4QC9EKZXG8 541714
Not listed 9800 Medical Center Dr, Rockville, MD 20850, USA
10/5/06 10/31/25 Duke University
Duke University is a top-ranked global institution dedicated to expanding the frontiers of knowledge and applying it in service to society. The university is home to about 13,000 undergraduate and graduate students and has a world-class faculty. Duke University's Office of Research Administration Division oversees and provides administrative support for the university's sponsored research and educational grants and contracts from the federal government and other sponsors. Through federal contract and grant awards, Duke University provides a diverse array of goods and services to various government agencies, including clinical research, biomedical studies, educational services, and advanced technological development.
Duke University has been awarded numerous federal contracts to provide a wide range of goods and services. As a prime contractor for the Centers for Disease Control and Prevention (CDC), Duke has conducted clinical research and immunization safety assessment services under an indefinite delivery indefinite quantity (IDIQ) vehicle. The university has also provided executive training services to the Federal Emergency Management Agency (FEMA). Duke has delivered brain research, educational services, and infrastructure support through awards from agencies like the Department of Veterans Affairs (VA), Defense Advanced Research Projects Agency (DARPA), National Aeronautics and Space Administration (NASA), and Department of the Navy. Many of Duke's contract awards have been set-aside free, without any specific socioeconomic designations. The university has collaborated with various partners on both prime and subcontracts to deliver these services.
Duke University has been awarded numerous federal grants to conduct critical research across various disciplines. These grants have enabled Duke to provide services spanning biomedical research, brain and neuroscience studies, cancer research, cardiovascular disease research, gene therapy development, climate and environmental science, behavioral and social science research, and many other areas. Key federal grant programs supporting Duke's research include extramural programs from the National Institutes of Health (NIH) institutes and centers, as well as programs from the National Science Foundation (NSF), Department of Defense agencies like the Defense Health Agency, and other federal research agencies. Duke has frequently collaborated with other universities, research institutions, and industry partners as either a prime or sub-awardee on these grants, contributing to groundbreaking research and scientific advancements.
The Defense Advanced Research Projects Agency (DARPA) awarded Duke University an Other Transaction (OT) indefinite delivery vehicle (IDV) contract called MEASQUIT, valued at $1,000,000, to provide research and development services related to measurement-based quantum information and transduction. No set-aside designations were used for this IDV award to Duke's Office of Research Administration Division, which serves as the prime contractor. The full scope of services Duke will provide under this IDV is not specified, but it aligns with Duke's expertise across various research domains applicable to government agencies. This IDV demonstrates Duke's capability to engage in cutting-edge research and development projects that have potential applications in advanced technologies for defense and national security purposes.
TP7EK8DZV6N5 611310
Not listed 2200 W Main St, Durham, NC 27705, USA
2/26/02 9/28/25